• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Guse Kyle claimed no ownership of stock in the company (SEC Form 3)

    8/15/25 4:19:37 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Guse Kyle

    (Last) (First) (Middle)
    C/O PLUS THERAPEUTICS INC.
    4200 MARATHON BOULEVARD, SUITE 200

    (Street)
    AUSTIN TX 78756

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/18/2025
    3. Issuer Name and Ticker or Trading Symbol
    PLUS THERAPEUTICS, INC. [ PSTV ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 0 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Andrew Sims, attorney-in-fact 08/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PSTV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

    D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

    3/17/25 7:41:57 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    HC Wainwright initiated coverage on Plus Therapeutics

    HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy

    2/11/21 7:44:56 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Plus Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00

    2/11/21 6:52:36 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    9/17/24 7:00:04 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    9/16/24 7:00:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    9/13/24 6:04:12 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    SEC Filings

    View All

    SEC Form 424B3 filed by PLUS THERAPEUTICS Inc.

    424B3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    8/15/25 4:26:12 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by PLUS THERAPEUTICS Inc.

    EFFECT - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    8/15/25 12:15:06 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by PLUS THERAPEUTICS Inc.

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    8/14/25 4:27:43 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

    REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the podium at the SNO/ASCO CNS Metastases Conference in Baltimore, MD. The data dem

    8/18/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

    HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"), as of June 30, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5 million in stockholders' equity. As previously reported, on June 3, 2025, the Nasdaq Listing Qualifications Department (the "Staff") notified the Company that, as of March 31, 2025, the Company no lo

    8/15/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

    Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. "The second quarter of 2025 marked steady execution and progress on our key strategic initiatives:  clinical development o

    8/14/25 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Guse Kyle

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/15/25 4:29:13 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Hedrick Marc H

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/15/25 4:29:11 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Lenk Robert P

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/15/25 4:29:07 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

    HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

    4/23/25 8:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

    AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic

    2/20/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

    Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a

    6/7/24 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

    SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    6/5/24 7:26:01 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/13/23 3:25:03 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/11/22 7:53:23 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

    Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. "The second quarter of 2025 marked steady execution and progress on our key strategic initiatives:  clinical development o

    8/14/25 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

    U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide"). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients s

    6/26/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

    HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call  Date/Time:Thursday, June 26, 2025 @ 9:00 AM ET Webcast: https://edge.media-server.com/mmc/p/97egitn8 Dial-in Link: https://register-conf.media-server.com/re

    6/25/25 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care